Abiopharma

🔍 SCHWARTZ NORMAN D (Director)

Company: BIO-RAD LABORATORIES, INC. (BIO BIO.B)

Report Date: 2025-09-01

Detailed Transactions and Holdings:

• Acquired 6,353 shares of Bio-Rad A Common Stock (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 444,591.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,084 shares of Bio-Rad A Common Stock at $297.88 per share (Direct)
  Date: 2025-09-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 441,507.00 | transaction_form_type: 4
• Holds 0 shares of Bio-Rad B Common Stock (Direct)
  Date: 2025-09-01 | Code: H | shares_owned_after: 361,466.00
• Holds 0 shares of Bio-Rad B Common Stock (Direct)
  Date: 2025-09-01 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 13,006.00 | Footnotes: F2
• Holds 0 shares of Bio-Rad B Common Stock (Direct)
  Date: 2025-09-01 | Code: H | nature_of_ownership: By Blue Raven Partners, L.P. | shares_owned_after: 4,060,054.00 | Footnotes: F3
• Sold 1,266 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Sold 2,082 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,082.00 | transaction_form_type: 4 | Footnotes: F4, F6, F6
• Sold 3,005 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,010.00 | transaction_form_type: 4 | Footnotes: F4, F7, F7

Footnotes:

• F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
• F2: The reporting person disclaims beneficial ownership of these shares.
• F3: The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
• F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
• F5: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
• F6: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
• F7: On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.